Grifols Reports Weaker Margins, Launches Fibrinogen Product and Sets €1.9–1.97B EBITDA Target
Grifols’ full-year 2025 gross margin weakened due to the Inflation Reduction Act and China market dynamics while revenue growth was driven by new strategic partnerships in Egypt (EMA approval for source plasma) and Canada. The company launched a fibrinogen concentrate in Europe, plans a U.S. rollout post-FDA approval, and set 2026 EBITDA guidance at €1.9–1.97 billion.
1. Margin Impact
Grifols’ 2025 gross margin declined compared with 2024, primarily due to cost pressures from the Inflation Reduction Act and shifting plasma economics in China, where market dynamics weighed on protein yields and pricing.
2. Strategic Partnerships
The company advanced partnerships in Egypt and Canada, highlighted by EMA approval for Egyptian source plasma, which is expected to boost plasma collection volumes and diversify supply chains across key regions.
3. Product Launches
In 2025 Grifols introduced a fibrinogen concentrate in Europe and is preparing a U.S. launch contingent on FDA approval, expanding its biopharma portfolio in high-value clotting products.
4. 2026 Outlook
Grifols guided 2026 EBITDA to €1.9–1.97 billion at a 25–25.5% margin, with focus on higher-margin markets, production efficiencies, debt refinancing in H1 2026, and potential share buybacks funded by free cash flow.